Full video transcriptClick to expand
Auto-generated transcript of @lovethyliverr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Happy Monday. I'm officially on week two of Turns That Piatide Compound. I didn't have any like
- 0:05really bad side effects except for the fact that my food noise was like completely gone.
- 0:10I just stepped outside to eat lunch on my lunch break. I got some Chick-fil-A five-girled nuggets.
- 0:16I'm doing half a pack of the buffalo sauce and then a small mac and cheese. If I were to eat all
- 0:24of this it would only be 375 calories but it has 28 grams of protein so we loved that.
- 0:31I literally have to set in a marm and turn mine myself to eat. The camera keeps shaking
- 0:38it's because my giant dog has walked around on our deck and it shakes the whole thing.
- 0:42I've been eating slower and putting the fork down between bites and it's hot as hell outside.
- 0:47What is happening when I do eat I'm making sure that I get enough protein and fiber in.
- 0:56I'm doing my truth up tie through IVRX and I do have the link in the bio if you want to kind of see
- 1:01if it's something that is going to work for you. I'm having a hell of a time cutting this chicken
- 1:06with a spoon. I did not wait myself yet since taking it because it's only been a week and I don't
- 1:09want to become obsessed with the skill. I was very nervous to start a turns that fatide but so far
- 1:17the lack of food noise I wish I would have started it sooner. I can't believe the number of stinking
- 1:24bugs that I'm looking at currently climbing on the outside of my house. I am still loosely
- 1:30following the Mediterranean diet but I have still been indulging in things that I love
- 1:35just small portions. Being mindful of chewing slower letting it digest and then seeing how
- 1:42I feel dropped a piece. Oden come. Good boy. Hey miss. Prim. Oh shit. Prim. I'd really like to figure
- 1:54out a recipe using protein to make muffins like I have a pumpkin pie protein powder. I want to make
- 2:01pumpkin pie protein muffins. If you don't have anybody with that recipe put it in the comments.
- 2:07Here comes the sun again. This is what I mean by eating healthy doesn't have to be terrible.
- 2:15Is mac and cheese the healthiest thing for you? No but in small portions. Enjoy it. Last bite.
- 2:24Hey I'm gonna snack on this for the next hour or so. The mac and cheese there are 12 grams of protein in it
- 2:29and again I'm trying to get all the protein that I can. I'll work on this for this way.
- 2:36Thanks for eating lunch with me. Bye.
GLP-1 drugs and fatty liver: what the evidence actually shows
Quick answer
The creator is in week two of compounded tirzepatide, a dual GLP-1/GIP receptor agonist, and reporting suppressed appetite and reduced food preoccupation consistent with the drug's known central and peripheral mechanisms. She is managing intake by prioritizing protein and fiber while following a loosely Mediterranean dietary pattern, which aligns with clinical guidance for preserving lean mass during GLP-1-assisted weight loss. The #fattyliver hashtag suggests a possible metabolic liver indication, which tirzepatide is being studied for but is not yet an FDA-approved use.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and fatty liver: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and fatty liver: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and fatty liver: what the evidence actually shows" from Samantha Brown 🌸 Liver Health. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is in week two of compounded tirzepatide, a dual GLP-1/GIP receptor agonist, and reporting suppressed appetite and reduced food preoccupation consistent with the drug's known central and peripheral mechanisms.
The reason this review is not generic is the source wording and the canonical claim label "glp1 i wish i would have started this sooner glp1community ivypar." In this clip, the useful excerpt is: "Happy Monday." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is in week two of compounded tirzepatide, a dual GLP-1/GIP receptor agonist, and reporting suppressed appetite and reduced food preoccupation consistent with the drug's known central and peripheral mechanisms.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is in week two of compounded tirzepatide, a dual GLP-1/GIP receptor agonist, and reporting suppressed appetite and reduced food preoccupation consistent with the drug's known central and peripheral mechanisms. She is managing intake by prioritizing protein and fiber while following a loosely Mediterranean dietary pattern, which aligns with clinical guidance for preserving lean mass during GLP-1-assisted weight loss. The #fattyliver hashtag suggests a possible metabolic liver indication, which tirzepatide is being studied for but is not yet an FDA-approved use.
- Tirzepatide's appetite-suppressing effects, including reduced food noise, are linked to its dual action on GLP-1 and GIP receptors in the brain; the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed statistically significant reductions in hunger scores.
- Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound; quality and dosing consistency depend entirely on the compounding pharmacy's standards.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tirzepatide's appetite-suppressing effects, including reduced food noise, are linked to its dual action on GLP-1 and GIP receptors in the brain; the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed statistically significant reductions in hunger scores.
- Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound; quality and dosing consistency depend entirely on the compounding pharmacy's standards.
- Protein intake during GLP-1 therapy is not just preference: research suggests GLP-1-related weight loss includes lean tissue loss, making 25-30g protein per meal a practical target to discuss with your prescriber.
- The #fattyliver angle has real science behind it: a 2024 Lancet study by Newsome et al. showed tirzepatide produced histological liver improvement in MASLD patients, but this requires clinical monitoring, not just a TikTok recommendation.
- Week two is early. Side effects including nausea, vomiting, and delayed gastric emptying often intensify as doses increase over the first 4-12 weeks.
- The FDA has signaled intent to restrict compounded GLP-1 drugs as shortage conditions are resolved, which could affect supply and access for patients currently on compounded versions.
- Eating behaviors she describes, slower eating, protein-first, small portions, have independent evidence supporting metabolic benefit regardless of medication use.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @lovethyliverr actually say?
She's one week into compounded tirzepatide through a telehealth service and the main thing she's reporting is that her "food noise was like completely gone." She's eating Chick-fil-A nuggets and mac and cheese in small portions, setting alarms to remind herself to eat, and tracking protein carefully. She's not weighing herself yet because she doesn't want to get "obsessed with the scale." She made no dramatic health claims, didn't cite a dose, and didn't claim she was cured of anything. For a sponsored GLP-1 video, this one is pretty grounded.
She also mentioned loosely following the Mediterranean diet, eating slower, putting her fork down between bites, and prioritizing protein and fiber. These are legitimate behavioral strategies, not filler content. The hashtag #fattyliver in the caption suggests she may be using tirzepatide partly for metabolic liver reasons, though she doesn't say this directly in the video.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Samantha Brown 🌸 Liver Health · TikTok creator
49.4K views on this video
I wish I would have started this sooner. #glp1community #ivypartner #fattyliver @IVY
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide's appetite-suppressing effects, including reduced food noise,?
Tirzepatide's appetite-suppressing effects, including reduced food noise, are linked to its dual action on GLP-1 and GIP receptors in the brain; the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed statistically significant reductions in hunger scores.
What does the video say about compounded tirzepatide?
Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound; quality and dosing consistency depend entirely on the compounding pharmacy's standards.
What does the video say about protein intake during glp-1 therapy?
Protein intake during GLP-1 therapy is not just preference: research suggests GLP-1-related weight loss includes lean tissue loss, making 25-30g protein per meal a practical target to discuss with your prescriber.
What does the video say about the #fattyliver angle has real science behind it: a 2024?
The #fattyliver angle has real science behind it: a 2024 Lancet study by Newsome et al. showed tirzepatide produced histological liver improvement in MASLD patients, but this requires clinical monitoring, not just a TikTok recommendation.
What does the video say about week two?
Week two is early. Side effects including nausea, vomiting, and delayed gastric emptying often intensify as doses increase over the first 4-12 weeks.
What does the video say about the fda has signaled intent to restrict compounded glp-1 drugs?
The FDA has signaled intent to restrict compounded GLP-1 drugs as shortage conditions are resolved, which could affect supply and access for patients currently on compounded versions.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Samantha Brown 🌸 Liver Health, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.